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Topical Corticosteroids in Early Mycosis Fungoides: When and How?
M Mori and N Pimpinelli
Department of Dermatological Sciences, University of Florence Medical School,
Florence, Italy
The treatment options for early mycosis fungoides (MF) should not be outside the
field of skin-directed therapies. In stage IA, and at a lesser extent in patch stage IB
MF, class I topical corticosteroids (TCs) – mostly clobetasol propionate – can be an
effective first-line treatment. Recent data showed an overall response of 94% (63%
CR) in stage IA MF patients. These data are worth of attention, even though long
term follow-up data are not available to date. In addition to the above, the possible
use of TCs in early MF or in later stage MF patients relapsing with few patches can
be considered as an integration to other treatment modalities (PUVA, narrow-band
UVB, topical chemotherapy). In this latter case, the clinical practice also suggest
the possible use of class II TCs, with a much lower risk of local and systemic side
effects. This is especially worth of consideration taking into account the higher
susceptibility to side effects of pretreated MF patients.
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Possible Involvement of Borrelia Burgdorferi and HCV in the Aethiology
of Mycosis Fungoides
G Trevisan*, S Bonin*$, S Tothova*$ and G Stanta*$
*Department of Clinical, Morphological and Technological Sciences-University of
Trieste, Trieste, Italy, $ICGEB-International Centre for Genetinc Engineering and
Biotechnology, Trieste, Italy
Mycosis fungoides is the most frequent cutaneous T-cell lymphoma with an
unknown etiology. Several aethiopathogenetic mechanisms have been postulated,
including persistent viral or bacterial infections. We looked for the presence of
Borrelia burgdorferi, an aethiologic agent of Lyme disease and Hepatitis C virus
(HCV) in a case study of mycosis fungoides patients from Northeastern Italy.
Polymerase chain reaction was used to detect Borrelia burgdorferi genome, while
RT-PCR was performed for HCV analysis. The case study was composed of
formalin-fixed and paraffin-embedded lesional skin biopsies of 83 patients with
mycosis fungoides and 83 sex- and age-matched healthy controls with homo-
localized cutaneous nevi. Borrelia burgdorferi-specific sequence was detected in
15 out of 83 skin samples of patients with mycosis fungoides (18.1%), but in none
out of 83 matched healthy controls (po0.0001). Positivity for HCV was detected in
4 out of 83 MF samples and in 3 out of 83 controls (p¼0.279). This study shows no
association between MF and HCV infection. Borrelia burgdorferi positivity rates
detected in this study support a possible role of Borrelia burgdorferi in the
aethiopathogenesis of mycosis fungoides in the population endemic for Lyme
disease.
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Measles Virus Oncolytic Activity in Cutaneous T-Cell Lymphoma – In
Vitro and In Vivo
V Ku¨nzi1, PA Oberholzer3, L Heinzerling2,3, R Dummer3, HY Naim1
1Berna Biotech AG, Bern, Switzerland, 2Present address: Department of Dermatol-
ogy and Allergy, Charite´-University Hospital, Berlin, Germany and 3Department of
Dermatology, University Hospital Zurich, Zurich, Switzerland
Measles virus has shown promise as an oncolytic virus in the treatment of different
tumor models for human B-cell lymphoma, multiple myeloma, ovarian cancer, and
glioma. In human cutaneous T-cell lymphoma (CTCLs) deficiency of neoplastic T-
lymphocytes in interferon signaling has been shown, thus rendering them
susceptible for viral oncolysis. We evaluated cytopathic effects of measles virus
(MV) in human CTCL cell lines in vitro and in vivo in a mouse tumor model of
human CTCL. CTCL cell lines originating from patients expressed MV receptors
CD150 and CD46 and were easily infected by MV, resulting in oncolysis in two cell
lines and slow reduction in viability of the third. CTCL tumors established from one
of these CTCL cell lines (MyLa) in nude mice where treated with recombinant MV.
Intratumoral treatment led to complete tumor regression in treated mice, while
control mice showed exponential tumor growth. Immunohistochemical analysis of
biopsies during intratumoral treatment with MV revealed local viral activity with
positive staining for MV NP protein. The data demonstrate the inherent potential of
MV as a therapeutic agent against CTCL with potential application in clinic.
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Primary Cutaneous T-Cell Anaplastic Large Cell Lymphoma CD30þ in
a Heart Transplant Patient: Report of a Case and Literature Review
M Alaibac, C Montesco, S Piaserico, F Tona and A Belloni Fortina
Unit of Dermatology, University of Padua, Italy
Solid organ transplant recipients are more at risk of developing a wide 0range of
malignancies including skin tumours and lymphoproliferative disorders. The risk of
post-transplant lymphoproliferative disorder (PTLD) is 28–49 times the risk of
lymphoproliferative disorder in the normal population. Most cases are of B-cell
phenotype and are associated with Epstein–Barr virus (EBV) infection. PTLD
presenting clinically in the skin are rare and usually of B-cell phenotype. Only rare
cases of cutaneous T-cell PTLD have been previously reported, mostly mycosis
fungoides type. We describe a rare primary cutaneous T-cell lymphoma CD30þ
arising in a hearth transplant patient who developed a solitary nodule on his right
leg 12 years following hearth transplantation. An excisional biopsy was performed
and the morphology and the immunohistochemical findings were consistent with a
CD30þ anaplastic large cell lymphoma with a T-cell phenotype. There was no
clinical evidence of systemic spread of the lymphoma. After the histological
diagnosis, radiotherapy in correspondence of the affected area was performed. In
our patient no further lesions appeared within 9 months. Knowledge of this rare T-
cell PTLD is limited, although from the review of the literature it seems that this
disorder has a propensity for a more aggressive course in immunosuppressed
patients.
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CD56 Lymphoproliferative Disorders of the Skin: A Multicenter Study
from the European Organization for Research and Treatment for Cancer
(EORTC) Cutaneous Lymphoma Project Group
C Assaf and W Sterry
Department of Dermatology and Allergy Skin Cancer Center Charite´, Charite´-
Universita¨tsmedizin Berlin, Germany
Cutaneous lymphomas expressing CD56, a neural cell adhesion molecule, are
characterized by a highly aggressive clinical course and a poor prognosis.
However, prognostic subsets within the CD56þ group have been difficult to
identify due to lack of uniform clinicopathological and immunophenotypical
criteria. To define prognostic parameters and guidelines for diagnosis and treatment
for CD56þ hematological neoplasms presenting primarily in the skin a multicenter
study was conducted by the cutaneous lymphoma task force of the EORTC. As a
result four different subtypes of lymphoproliferations with CD56 expression could
be identified: 1) hematodermic neoplasm, 2) skin infiltration as first manifestation of
CD56þ acute myeloid leukemias, 3) extranodal NK/T-cell lymphoma, nasal type
and, 4) ‘‘classical’’ cases of cutaneous T-cell lymphoma (CTCL) with co-expression
of the CD56 molecule. Patients of the first three groups had a poor outcome (93%
died) with a median survival rate of 11 months (confidence interval 2–72 months),
whereas all patients of the last group were alive at the last follow-up. Our findings
indicate that CD56þ cutaneous lymphoproliferative disorders presenting in the
skin have a poor prognosis. However, ‘‘classical CTCL’’ cases can show co-
expression of this molecule, which does not affect the indolent clinical course.
These cases should not be mistaken as CD56þ aggressive neoplasms and therefore
aggressive treatment should be avoided.
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Photodynamic Therapy with Methyl Aminolevulinate as a Valuable
Treatment Option for Unilesional Cutaneous T Cell Lymphoma
M Venturini, R Sala, C Zane and PG Calzavara-Pinton
Department of Dermatology, Spedali Civili, Brescia, Italy
Background: Mycosis fungoides (MF) is the most common primary Cutaneous T cell
Lymphoma (CTCL). Unilesional MF is characterized by a limited involvement of the
skin and a chronic though indolent course. If lesions are refractory to topical
steroids, therapies such as localized chemotherapy, photochemotherapy and
radiotherapy are available. However, they have several acute and chronic side-
effects and toxicity may accumulate if repeated and protracted treatment cycles are
delivered to refractory or relapsing lesions. The present study aims to assess the
efficacy of photodynamic therapy (PDT) with topical methyl-aminolevulinate
(MAL) in the treatment of unilesional MF. Methods: Five patients were enrolled who
were suffering from unilesional MF which did not respond to treatment with topical
steroids, localized PUVA or UVA1 phototherapies. A 20% MAL (Metvix creams,
Galderma, F) cream was applied under occlusive dressing for 3 hours. Soon
afterwards, skin was irradiated with 37.5 J/cm2 of red light (635718 nm) delivered
by an Aktilite CL128 lamp (PhotoCure ASA, Oslo, Norway) with an irradiance of
86 W/cm2 at skin level. PDT was repeated once weekly until complete clearing of
the lesions was obtained, or, in the case of partial clearing, the therapy was
interupted when 3 successive treatments provided no further improvement. All
patients underwent a skin biopsy before and after PDT. Results: A complete
remission was observed in 4 patients and a partial improvement in 1. The median
number of treatments was 6 (range 1–9). In no cases was recurrence seen at follow-
up (ranging from 12 to 34 months). Treatments were well tolerated and local
anaesthesia was never requested. Conclusion: In conclusion, PDT was here seen to
be an effective and well tolerated treatment option for unilesional MF.
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Methyl Aminolevulinate Photodynamic Therapy (MAL-PDT) for the
Treatment of Early Stage Mycosis Fungoides
M Teoli, M Papoutsaki, A Giunta, E Botti, C Schipani, M Montaldo, L Bianchi,
A Livin and S Chimenti
Department of Dermatology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
Therapy for mycosis fungoides (MF) is based on clinical stage. Although treatments
for early or localized patch stage MF may appear to result in cure, the practical aim
is to achieve and maintain clinical remission, decrease morbidity, and palliate
advanced disease. Multiple therapeutic modalities exist, from topical therapy,
phototherapy, photopheresis, radiation therapy, immunotherapy, chemotherapy, or
newer agents such as anti-tumor vaccines and antibody fusion toxins. Photo-
dynamic therapy (PDT) is a developing approach to the treatment of cancer and
other diseases that involves the use of light to activate photosensitizer molecules.
Topical agents such as methyl aminolevulinate (MAL) may be used for the PDT, as
it acts as powerful photosensitiser. Isolated reports of efficacy were reported for
treating cutaneous T-cell lymphomas. It has been shown that PDT inhibits the
proliferation of malignant lymphocytes. Here we report the use of MAL-PDT in 4
patients affected by MF (Stage Ia, Ib, IIa), recalcitrant to other treatments. Patients
were treated with MAL cream (160 mg/g) and 75 J/cm2 red light (570-670 nm) and
the number of repetitions were individually chosen in reaction to the individual
tolerability and clinical outcome. Adverse events, such as erythema, edema and
crust formation, were mild to moderate, and treatment was well tolerated. The
results are discussed. In our preliminary experience MAL-PDT led to partial
remission in localized lesions and further investigation regarding its role as a
possible useful addition to standard therapies is needed. Further studies are
necessary in order to determine the optimal light dose and treatment interval.
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Final Results of a Phase I/II Multicentric Trial of Adenovirus-Interferon-c
(TG1042) Demonstrate Good Tolerance and Efficacy in Relapsing
Primary Cutaneous Lymphoma (PCL)
M Urosevic1, B Dreno2, C Assaf3, M Schiller4, O Dereure5, M Baudard6, M Bagot7,
A Khammari2, V Bataille8, P Bleuzen8 and R Dummer1
1University Hospital, Zurich, Switzerland, 2University Hospital, Nantes, France,
3Charite Hospital, Berlin, Germany, 4University Hospital, Munster, Germany, 5St
Eloi Hospital, Montpellier, France, 6Lapeyronie Hospital, Montpellier, France,
7Henri Mondor Hospital, Creteil, France and 8Transgene, Strasbourg, France
Interferons (IFNs) have been successfully used to treat PCL. We undertook a phase I/
II multicentric trial of repeated, intratumoral (i.t.) injection of TG1042 (a non-
replicating recombinant adenovirus with a human IFN-g cDNA insert) in patients
with advanced primary T cell (CTCL) or B cell (CBCL) CL. One to 3 lesions were
injected on day 1, 8, and 15 with no treatment during the 4th week (a 4- week
cycle) and thereafter up to 12 cycles. Immunohistochemistry and quantitative PCR
were performed on injected lesions biopsied at baseline and after the 1st cycle. In
the phase I, 18 patients were enrolled in 3 successive cohorts at the doses of 3x109
viral particles (vp) (n¼3), 3x1010 vp (n¼3) and 3x1011 vp (n¼12). In the phase
II, 21 patients have been treated at 3x1011 vp. To date, enrolment is completed, 39
patients (32 CTCL and 7 CBCL) have been included, 3 of them are still on
treatment. Injection site reaction and flu like syndrome and fatigue were the most
common adverse events. Transgene-IFN-g mRNA was detected in injected lesions.
Gene expression analysis of biopsies and PBMC showed up-regulation of IFN-g-
inducible genes. Local clinical response has been observed in 17 (including 9
complete responses(CR)) out of 31 evaluable patients. Thirteen global responses (7
CR) out of 30 evaluable patients have been observed. All 5 evaluable CBCL
responded (3 CR). These results demonstrate that TG1042 is well tolerated and
presents a potential significant benefit for the treatment of both CTCL and CBCL.
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